Prague Med. Rep. 2023, 124, 444-448
https://doi.org/10.14712/23362936.2023.34
Demonstration of the Rationale for Therapeutic Drug Monitoring of Isavuconazole: A Case Report with a Lung Transplant Recipient
References
1. , A. V., Kovanda, L. L., Hope, W. W., Andes, D., Mouton, J. W., Kowalski, D. L., Townsend, R. W., Mujais, S., Bonate, P. L. (2017) Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi. Antimicrob. Agents Chemother. 61(12), e01034-17.
<https://doi.org/10.1128/AAC.01034-17>
2. EMA (2015) Cresemba: Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/cresemba-epar-product-information_en.pdf
3. EUCAST (2020) Breakpoint tables for interpretation of MICs for antifungal agents. Version 10.0. Available at: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Clinical_breakpoints/AFST_BP_v10.0_200204_updatd_links_200924.pdf
4. , E., Signori, A., Di Grazia, C., Dominietto, A., Raiola, A. M., Aquino, S., Ghiggi, C., Ghiso, A., Ungaro, R., Angelucci, E., Viscoli, C., Mikulska, M. (2019) Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy. J. Antimicrob. Chemother. 74(8), 2341–2346.
<https://doi.org/10.1093/jac/dkz188>
5. , F. M., Ostrosky-Zeichner, L., Cornely, O. A., Mullane, K. M., Perfect, J. R., Thompson, G. R. 3rd, Alangaden, G. J., Brown, J. M., Fredricks, D. N., Heinz, W. J., Herbrecht, R., Klimko, N., Klyasova, G., Maertens, J. A., Melinkeri, S. R., Oren, I., Pappas, P. G., Racil, Z., Rahav, G., Santos, R., Schwartz, S., Vehreschild, J. J., Young, J. H., Chetchotisakd, P., Jaruratanasirikul, S., Kanj, S. S., Engelhardt, M., Kaufhold, A., Ito, M., Lee, M., Sasse, C., Maher, R. M., Zeiher, B., Vehreschild, M. J. G. T.; VITAL and FungiScope Mucormycosis Investigators (2016) Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis. Lancet Infect. Dis. 16(7), 828–837.
<https://doi.org/10.1016/S1473-3099(16)00071-2>
6. , A., Los-Arcos, I., Martin-Gomez, M. T., Campany-Herrero, D., Sacanell, J., Berastegui, C., Marquez-Algaba, E., Sempere, A., Nuvials, X., Deu, M., Castells, L., Moreso, F., Bravo, C., Gavalda, J., Len, O. (2022) Safety and effectiveness of isavuconazole treatment for fungal infections in solid organ transplant recipients (ISASOT study). Microbiol. Spectr. 10(1), e0178421.
<https://doi.org/10.1128/spectrum.01784-21>
7. , P. G., Alexander, B. D., Andes, D. R., Hadley, S., Kauffman, C. A., Freifeld, A., Anaissie, E. J., Brumble, L. M., Herwaldt, L., Ito, J., Kontoyiannis, D. P., Lyon, G. M., Marr, K. A., Morrison, V. A., Park, B. J., Patterson, T. F., Perl, T. M., Oster, R. A., Schuster, M. G., Walker, R., Walsh, T. J., Wannemuehler, K. A., Chiller, T. M. (2010) Invasive fungal infections among organ transplant recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 50(8), 1101–1111.
<https://doi.org/10.1086/651262>
8. , A., Roos, B., Maares, J., Heep, M., Spickerman, J., Weidekamm, E., Brown, T., Roehrle, M. (2006) Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob. Agents Chemother. 50(1), 286–293.
<https://doi.org/10.1128/AAC.50.1.286-293.2006>
9. , X., Clancy, C. J., Rivosecchi, R. M., Zhao, W., Shields, R. K., Marini, R. V., Venkataramanan, R., Nguyen, M. H. (2018) Pharmacokinetics of intravenous isavuconazole in solid-organ transplant recipients. Antimicrob. Agents Chemother. 62(12), e01643-18.
